The effect of Bifidobacterium longum on PPI-based triple therapy for eradication of Helicobacter pylori.

Phase 4

Completed

• Conditions: Helicobacter pylori positive gastritis patients; Helicobacter pylori, gastritis, probiotic

• Registration Number: TCTR20200804008
• Lead Sponsor: Chiang Mai University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2020-06-26
• Study Start: 2020-08-04
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1.18-50 years of age.
2.Dyspeptic symptoms more than 4 weeks.
3.Endoscopy reveals Helicobacter pylori infection by rapid urease test or histology by hematoxylin and eosin staining.
4.No serious medical condition.
5.Volunteer has been instructed and is willing to provide written informed consent to participate in the study.

Exclusion Criteria

1.Allergy or have any contraindication to milk protein.
2.Recent use (within 4 weeks) prior to study entry of H2RAs, proton pump inhibitors or any other medication that affect acid secretion.
3.Recent use (within 4 weeks) prior to study entry of any NSAIDs, corticosteroids, anticholinergics or anticoagulants.
4.Any other conditions that the investigator feels would interfere with an endoscope and study procedure.

Study & Design

• Study Type: Interventional
• Study Design: Not specified